JP2006505530A5 - - Google Patents

Download PDF

Info

Publication number
JP2006505530A5
JP2006505530A5 JP2004532517A JP2004532517A JP2006505530A5 JP 2006505530 A5 JP2006505530 A5 JP 2006505530A5 JP 2004532517 A JP2004532517 A JP 2004532517A JP 2004532517 A JP2004532517 A JP 2004532517A JP 2006505530 A5 JP2006505530 A5 JP 2006505530A5
Authority
JP
Japan
Prior art keywords
azabicyclo
oct
carboxamide
octane
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004532517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505530A (ja
Filing date
Publication date
Priority claimed from SE0202598A external-priority patent/SE0202598D0/xx
Application filed filed Critical
Publication of JP2006505530A publication Critical patent/JP2006505530A/ja
Publication of JP2006505530A5 publication Critical patent/JP2006505530A5/ja
Abandoned legal-status Critical Current

Links

JP2004532517A 2002-09-02 2003-09-01 アルファ−7ニコチン受容体作用剤およびスタチンの組み合わせ Abandoned JP2006505530A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202598A SE0202598D0 (sv) 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination
PCT/SE2003/001352 WO2004019947A1 (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and statins in combination

Publications (2)

Publication Number Publication Date
JP2006505530A JP2006505530A (ja) 2006-02-16
JP2006505530A5 true JP2006505530A5 (https=) 2006-10-19

Family

ID=20288874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004532517A Abandoned JP2006505530A (ja) 2002-09-02 2003-09-01 アルファ−7ニコチン受容体作用剤およびスタチンの組み合わせ

Country Status (12)

Country Link
US (2) US20050256146A1 (https=)
EP (1) EP1545537B9 (https=)
JP (1) JP2006505530A (https=)
AT (1) ATE358485T1 (https=)
AU (1) AU2003256203A1 (https=)
DE (1) DE60313004T2 (https=)
DK (1) DK1545537T3 (https=)
ES (1) ES2283860T3 (https=)
PT (1) PT1545537E (https=)
SE (1) SE0202598D0 (https=)
SI (1) SI1545537T1 (https=)
WO (1) WO2004019947A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
JP5996532B2 (ja) * 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Tlr阻害作用を有するチオフェン誘導体
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited ムスカリンm4受容体アゴニストとしてのピペリジン−1−イル及びアゼピン−1−イルカルボキシレート
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
US20210255202A1 (en) * 2018-06-13 2021-08-19 Michael R. D'Andrea Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE192157T1 (de) * 1994-08-24 2000-05-15 Astra Ab Therapeutisch verwendbare spiro-azabicyclische verbindungen
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903996D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
AU2001282875A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
US20050222122A1 (en) * 2002-04-02 2005-10-06 Sean Lilienfeld Statin therapy for enhancing cognitive maintenance
PL377777A1 (pl) * 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
EP1735306A2 (en) * 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof

Similar Documents

Publication Publication Date Title
JP2006505530A5 (https=)
US20090192180A1 (en) Alpha-7 Nicotinic Receptor Agonists and Statins In Combination
RU2002118302A (ru) Новые биарилкарбоксамиды
CA2514135A1 (en) 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
JP2003514818A5 (https=)
JP2002523502A5 (https=)
RU2008148902A (ru) Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3)
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
JP2012523437A5 (https=)
HRP20171793T1 (hr) Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata
AU2007271186B2 (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
JP2008526861A5 (https=)
JP2009514802A5 (https=)
JP2014503568A (ja) ニコチン酸アセチルコリン受容体α7活性化因子の使用
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
FI3707143T3 (fi) Uusia analogeja androgeenireseptorin ja glukokortikoidireseptorin modulaattoreina
JP2025504916A5 (https=)
CN105263492B (zh) α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
RU2007134414A (ru) Бензоксазолкарбоксамиды для лечения индуцированной химиотерапией тошноты и рвоты (cini) и синдрома раздраженного кишечника с преобладанием диареи (ibs-d)
RU2007126638A (ru) Профилактическое или терапевтическое средство для лечения расстройства сна
JP2003055360A5 (https=)
JP2005510482A5 (ja) 線維筋痛症候群の治療用医薬
ZA200407896B (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
AU2012232711B2 (en) Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
CA2484276A1 (en) Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases